更新于：2024-09-19

Epilepsy, Partial, Sensory

部分性感觉性癫痫

更新于：2024-09-19

基本信息

别名

Epilepsy, Partial, Sensory、Epilepsy, Sensory Partial、Focal Seizure Disorder, Sensory

+ [46]

简介

A disorder characterized by recurrent focal onset seizures which have sensory (i.e., olfactory, visual, tactile, gustatory, or auditory) manifestations. Partial seizures that feature alterations of consciousness are referred to as complex partial seizures (EPILEPSY, COMPLEX PARTIAL).

关联

项与部分性感觉性癫痫相关的临床试验

NCT05847816 / Not yet recruitingN/AIIT

The Effects of Three Different Techniques During Peripheral Intravenous Cannulation (PIVC) Administered in Vein Visibility, Pain and Comfort in Cancer Patients Receiving Palliative Care

Purpose: This study will conducted to the effect of three different techniques used during peripheral intravenous cannulation (PIVC) application on vein visibility, pain and comfort in cancer patients receiving palliative care.
Design: This is a prospective, randomized controlled experimental study. Methods: The population of the research will be cancer patients who applied to Ege University Medical Faculty Hospital Oncology unit between April 2023 and November 2024. The number of applications due to palliative care and cancer treatment in the clinic in 2021 is 352 patients. For this reason, direct sample selection was not made in the study, and the sample calculation was made according to the number of patients registered in the unit and the results of previous research (Chiao et al., 2013; Aulagnier et al., 2014). Calculations were made using the "G.Power-3.17" program with 95% confidence, an effect size of 0.4, and a statistical test power of at least 80%. Accordingly, it was aimed to reach 120 patients, including at least 40 in each group. In the study, randomization will be made according to vein visibility.

开始日期2023-05-17

申办/合作机构

Ege Universitesi

NCT04184726 / CompletedN/AIIT

Mindfulness Based Cognitive Therapy Modified for Visual Symptoms: MBCT-vision

This is a research study on Mindfulness-Based Cognitive Therapy for visual symptoms (MBCT-vision), to treat patients with debilitating symptoms of visual snow (VS) and is associated visual symptoms, severe light sensitivity (i.e. photophobia) and migrainous visual aura.
Participants will receive an intervention of an 8-week MBCT course modified for visual symptoms, which will involve 8 weeks of once weekly group sessions and home practice between sessions.

开始日期2020-01-09

申办/合作机构

Guy's & St Thomas' Charity

NCT03350932 / CompletedN/AIIT

Evaluation of the Effect of Sensory Imagination on Choice of Food Portion Size in School-aged Children

The objective of this intervention is to evaluate the effect of sensory imagination (i.e., imagining the sensory properties of an object) on the choice of food portion size in school-aged children. Previous research showed that it may help children to choose smaller portion size. The investigators would like to assess whether this effect can be reproduced with two types of food (one with a high energy-density and one with a low energy-density), and in older children.

开始日期2017-02-16

申办/合作机构-

100 项与部分性感觉性癫痫相关的临床结果

登录后查看更多信息

100 项与部分性感觉性癫痫相关的转化医学

登录后查看更多信息

0 项与部分性感觉性癫痫相关的专利（医药）

登录后查看更多信息

331

项与部分性感觉性癫痫相关的文献（医药）

2024-02-02·European eating disorders review : the journal of the Eating Disorders Association

Analysis of feeding and eating disorders in 191 children according to psychiatric or gastroenterological recruitment: The PEDIAFED cohort study.

Article

作者: Valérie Bertrand ; Marie-Pierre Tavolacci ; Anne Bargiacchi ; Véronique Leblanc ; Pierre Déchelotte ; Coline Stordeur ; Marc Bellaïche

OBJECTIVE:

The DSM-5 classification introduced new Feeding and Eating Disorders (FED) diagnostic categories, notably Avoidant and Restrictive Food Intake Disorder (ARFID), which, like other FED, can present psychiatric and gastrointestinal symptoms. However, paediatric clinical research that focuses on children below the age of 12 years remains scarce. The aim of this study was first to investigate the clinical features of FED in a cohort of children, second to compare them according to their recruitment (gastroenterology or psychiatry unit).

METHOD:

This non-interventional retrospective cohort study analysed 191 patients in a French paediatric tertiary care centre (gastroenterology n = 100, psychiatry n = 91). The main outcome variables were clinical data (type of FED, BMI, nutritional support, chronic diseases, psychiatric comorbidities, sensory, sleep, language disorders, gastrointestinal complaints, adverse life events, family history). The outcome was defined by a Clinical Global Impression of Change-score.

RESULTS:

FED diagnoses were ARFID (n = 100), Unspecified FED (UFED, n = 57), anorexia nervosa (AN, n = 33) and one pica/rumination. Mean follow-up was 3.28 years (SD 1.91). ARFID was associated with selective and sensory disorders (p < 0.001); they had more anxiety disorders than patients with UFED (p < 0.001). Patients with UFED had more chewing difficulties, language disorder (p < 0.001), and more FED related to chronic disease (p < 0.05) than patients with ARFID and AN. Patients with AN were female, underweight, referred exclusively to the psychiatrist, and had more depression than patients with ARFID and UFED (p < 0.001). The gastroenterology cohort included more UFED, while the psychiatry cohort included more psychiatric comorbidities (p < 0.001). A worse clinical outcome was associated with ARFID, a younger age at onset (p < 0.001), selective/sensory disorders and nutritional support (p < 0.05).

CONCLUSION:

ARFID and UFED children were diagnosed either by gastroenterologists or psychiatrists. Due to frequently associated somatic and psychiatric comorbidities, children with FED should benefit from a multidisciplinary assessment and care.

2024-01-02·The International journal of neuroscience

Migraine-like headache in subjects with isolated Lambl's excrescences：a case series and literature review.

Article

作者: Wei Xie ; Xiaoguang Wang ; Ruibing Li ; Zhihua Jia ; Shuai Miao ; Yang Liu ; Chunxiao Yang ; Chenhao Li ; He Zhao ; Ruozhuo Liu ; Shengyuan Yu

Aim: Lambl's excrescences are mobile, thin, fibrinous connective tissue strands typically found on left-sided cardiac values. Migraine is positively associated with structural cardiac anomalies. However, it remains unclear whether Lambl's excrescences are associated with migraine.Methods: Retrospective review of 182 inpatients with Lambl's excrescences confirmed by transesophageal echocardiogram in Chinese PLA General Hospital since January 2010. Among them, those with isolated Lambl's excrescences presented with migraine-like headache were included. We collected information on the demographics and clinical profiles of all participants, and performed follow-up visits.Results: A total of 8 patients presented with migraine-like headache among 15 patients with isolated Lambl's excrescences. They included 2 men and 6 women, with an average age of 44.63 ± 12.24 years. Among these patients, 3 had visual aura, and 6 manifested infarct-like lesions on magnetic resonance imaging, of which 2 developed lesions after first visit. During follow-up, 4 patients suffering from intervention for Lambl's excrescences dramatically reduced headache recurrence compared to the other 4 patients only receiving migraine preventive medications.Conclusions: This study supports the hypothesis that microemboli from isolated Lambl's excrescences could cause migraine-like headache. And intervention for Lambl's excrescences may be crucial for preventing headache recurrence.

2024-01-01·Cephalalgia : an international journal of headache

Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses.

Article

作者: David M Niddam ; Kuan-Lin Lai ; Yi-Ting Hsiao ; Yen-Feng Wang ; Shuu-Jiun Wang

BACKGROUND:

The visual cortex is involved in the generation of migraine aura. Voxel-based multivariate analyses applied to this region may provide complementary information about aura mechanisms relative to the commonly used mass-univariate analyses.

METHODS:

Structural images constrained within the functional resting-state visual networks were obtained in migraine patients with (n = 50) and without (n = 50) visual aura and healthy controls (n = 50). The masked images entered a multivariate analysis in which Gaussian process classification was used to generate pairwise models. Generalizability was assessed by five-fold cross-validation and non-parametric permutation tests were used to estimate significance levels. A univariate voxel-based morphometry analysis was also performed.

RESULTS:

A multivariate pattern of grey matter voxels within the ventral medial visual network contained significant information related to the diagnosis of migraine with visual aura (aura vs. healthy controls: classification accuracy = 78%, p < 0.001; area under the curve = 0.84, p < 0.001; migraine with aura vs. without aura: classification accuracy = 71%, p < 0.001; area under the curve = 0.73, p < 0.003). Furthermore, patients with visual aura exhibited increased grey matter volume in the medial occipital cortex compared to the two other groups.

CONCLUSIONS:

Migraine with visual aura is characterized by multivariate and univariate patterns of grey matter changes within the medial occipital cortex that have discriminative power and may reflect pathological mechanisms.

项与部分性感觉性癫痫相关的新闻（医药）

2023-12-08

·GlobeNewswire-Health Care

Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment

Bsense Bio Therapeutics Ltd., a preclinical-stage biopharmaceutical company developing innovative small molecule drug candidates for sensory hyperexcitability disorders, today announced the clinical candidate nomination of their drug candidate, BSEN760, a dual Kv7.2/3 and TRPV1 ion-channel modulator, which heralds a potential breakthrough in the treatment of chronic pain by potentially providing efficacy for a broad spectrum of chronic pain conditions devoid of side effects associated with current standard-of-care (SOC) treatments. BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1. The dual mechanism of action (MOA) of BSEN760 underlies the compound’s exquisite potency and synergistic activity in dampening sensory neuron hyperexcitability. Kv7.2/3 and TRPV1 are highly validated therapeutic targets for modulation of sensory hyperexcitability, specifically for pain alleviation; however, significant CNS, renal and thermal side effects have limited successful translation of numerous Kv7.2/3 and TRPV1 drug development programs. The Company’s novel MOA, targeting dual ion-channel modulation, is particularly advantageous compared to current SOC drugs due to its efficacy in models of chronic pain at low (sub-nanomolar) exposures that translate to a wide therapeutic window avoiding side effects. As such, BSEN760 may enter the market with comparable, potentially better, efficacy vs. SOC, and a much improved safety profile. Preclinical studies of BSEN760 demonstrate dose-proportional efficacy in neuropathic and osteoarthritis pain models. Moreover, BSEN760 shows no evidence of motoric impairment/sedation (rotarod) nor effects on core body temperature and thermal sensation, side effects that have precluded clinical development of drugs targeting either Kv7.2/3 or TRPV1. These, and other data, support the Company’s efforts toward full preclinical development of BSEN760 and IND submission by Q1 2025. Haim Belinson PhD., Chief Scientific Officer of Bsense, commented: “The nomination of our dual Kv7.2/3-TRPV1 ion-channel modulator drug candidate, BSEN760, is an exciting step forward for Bsense Bio Therapeutics and the treatment of chronic pain conditions in general. With its unique features of modulating sensory nervous system hyperexcitability by two well validated pain MOAs but without class-related side effects, this asset shows unmatched potential to provide a superior, non-addictive treatment option for chronic pain. We look forward to bringing BSEN760 to the clinic in Q1, 2025 as we work to complete IND-enabling studies.” Alan Brown, Director, AD Brown Medchem Consulting Limited, added: “The exciting pharmacological profile and medicinal chemistry development behind BSEN760 suggest that this compound represents a significant step forward in the development of new pain therapeutics.” Vladimir Skljarevski M.D., Clinical consultant, Principal of VS Biopharma Consulting Inc.: “This novel and unique mechanism of action, involving modulation of two co-located ion-channels, has a potential to provide significant clinical analgesia across a broad range of chronic pain conditions with no addiction/abuse potential.” Sensory hyperexcitability translates to an increase in sensory stimuli, such as proprioception, vision, sound, and touch, as unpleasantly heightened sensations. Pathophysiology could arise from nerve damage, inflammation, and metabolic diseases, all of which may alter the normal function of sensory neurons. Sensory hyperexcitability is observed in a wide variety of neurological disorders, including Epilepsy, Anxiety, Autism, Pain, Tinnitus, and Pruritus to name a few. Sensory hyperexcitability related disorders impact millions of people worldwide. Moreover, these conditions have a profound negative effect on the quality of life of patients and place a significant operational and economic burden on healthcare systems. The multitude of patients suffering from sensory hyperexcitability disorders emphasizes a significant unmet medical need that ranges from a lack of effective pharmacological treatment (i.e., Tinnitus, various Pruritic conditions) to those, in particular chronic pain, with multiple available pharmacological treatments but that demonstrate less-than optimal efficacy often associated with significant side effects as well as, for some, the potential for drug abuse and addiction. In each case, the spatial and mechanistic emergence of sensory hyperexcitability may lead to different and varied clinical manifestations; however, in all cases, the sensory neuronal system’s excessive activity is the hallmark of the disorder. Importantly, the anatomical positioning of dorsal root ganglia (DRG) outside the CNS blood-nerve barrier has made signal transmission and transduction by afferent sensory neurons a prime target for modulating pain signaling to the spinal cord and higher brain centers. As such, modulation of hyperexcitability at the level of DRG neurons where Kv7.2/3 and TRPV1 are predominantly, and mutually, expressed represents a unique, synergistic approach toward providing significant relief coupled with superior tolerability to sensory hyperexcitability disorders. Bsense Bio Therapeutics is developing dual cationic channel small molecule modulators for the treatment of sensory hyperexcitability-related disorders. The goal of the Company’s novel, pioneering approach of targeting multiple neuronal excitability-related mechanisms using a single compound is to achieve greater efficacy and safety compared to current therapeutic approaches that focus on modulation of a single target. Bsense Bio’s approach is based on the targeting of two cation channels, TRPV1 and Kv7.2/3, a ligand-gated and a voltage-gated potassium channel, respectively, which are co-localized on sensory neurons and are widely recognized as prominent players in controlling neuronal excitability. Bsense Bio was established based on the initial discovery and identification by Prof. Bernard Attali and Dr. Asher Peretz from Tel-Aviv University of small molecule compounds demonstrating dual ion-channel activity. Bsense Bio was founded in September 2018 at the FutuRx biotech incubator and is financed by RMGP, OrbiMed Israel Partners, Johnson & Johnson Innovation – JJDC, Takeda Ventures Inc., and the Israeli Innovation Authority (IIA). The content above comes from the network. if any infringement, please contact us to modify.